£2m UK consortium to tackle gene therapy – PharmaTimes
PharmaTimes |
£2m UK consortium to tackle gene therapy
PharmaTimes A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing. Other partners include the Cell and Gene Therapy Catapult, Stratophase and Synthace, and the collaboration is … Oxford BioMedica to lead £2m gene therapy collaboration project |
